Direct KRAS inhibitors offer several advantages, including targeted therapy that specifically attacks cancer cells with mutant KRAS, potentially leading to fewer side effects compared to traditional chemotherapy. Additionally, these inhibitors provide new treatment options for patients with limited alternatives.
